A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here are three cash-producing companies to avoid and some better opportunities instead.
Laureate Education (LAUR)
Trailing 12-Month Free Cash Flow Margin: 15.2%
Founded in 1998 by Douglas L. Becker and based in Miami, Laureate Education (NASDAQ:LAUR) is a global network of higher education institutions.
Why Do We Pass on LAUR?
- Sluggish trends in its enrolled students suggest customers aren’t adopting its solutions as quickly as the company hoped
- Performance over the past five years shows its incremental sales were less profitable, as its 4.2% annual earnings per share growth trailed its revenue gains
- Free cash flow margin is not anticipated to grow over the next year
Laureate Education is trading at $32.28 per share, or 14.9x forward P/E. To fully understand why you should be careful with LAUR, check out our full research report (it’s free).
Cummins (CMI)
Trailing 12-Month Free Cash Flow Margin: 7.5%
With more than half of the heavy-duty truck market using its engines at one point, Cummins (NYSE:CMI) offers engines and power systems.
Why Is CMI Not Exciting?
- Flat sales over the last two years suggest it must find different ways to grow during this cycle
- High input costs result in an inferior gross margin of 24.7% that must be offset through higher volumes
- Diminishing returns on capital suggest its earlier profit pools are drying up
At $679.00 per share, Cummins trades at 23.2x forward P/E. Check out our free in-depth research report to learn more about why CMI doesn’t pass our bar.
Omnicell (OMCL)
Trailing 12-Month Free Cash Flow Margin: 9.3%
Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.
Why Do We Steer Clear of OMCL?
- Muted 5.4% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 6.8% annually while its revenue grew
- Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its decreasing returns suggest its historical profit centers are aging
Omnicell’s stock price of $43.69 implies a valuation ratio of 23.3x forward P/E. Dive into our free research report to see why there are better opportunities than OMCL.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.